Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Priority Review to CPX-351 for AML

June 1st 2017

The FDA has accepted a new drug application from Jazz Pharmaceuticals, granting priority review to the company’s novel CPX-351 injection (Vyxeos) for acute myeloid leukemia.

Treatment of Primary Myelofibrosis

May 31st 2017

Primary Myelofibrosis Disease State

May 31st 2017

Emerging Therapies for Polycythemia Vera

May 31st 2017

Failure of Polycythemia Vera Control with Phlebotomy

May 31st 2017

Response to Ruxolitinib Therapy for Polycythemia Vera

May 31st 2017

Relapsed or Refractory Polycythemia Vera

May 31st 2017

Practical Considerations of Polycythemia Vera Treatment

May 31st 2017

Therapeutic Options for Polycythemia Vera

May 31st 2017

Initiating Treatment for Polycythemia Vera

May 31st 2017

Polycythemia Vera Diagnosis

May 31st 2017

Risk Factors and Prognosis of Polycythemia Vera

May 31st 2017

Heterogeneity of Polycythemia Vera

May 31st 2017

Dr. Shah on Status of CAR T-cell Therapies in ALL

May 26th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

May 23rd 2017

Daniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.

Expert Sheds Light on Rare Complement-Mediated Hematologic Disorders

May 18th 2017

Ronald S. Go, MD, provides perspective on thrombotic microangiopathy and paroxysmal nocturnal hemoglobinuria, including how community physicians can properly diagnose and treat them.

Emerging BTK Inhibitor Tested in B-Cell Malignancies

May 18th 2017

BGB-3111, a second-generation BTK inhibitor, is being tested in patients with refractory B-cell lymphoid malignancies in an effort to determine whether the novel oral small molecule is a viable therapeutic option and to better understand its pharmacologic properties.

CLL-IPI an Essential Tool for Determining Treatment Approaches

May 17th 2017

Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.

Dr. Begna on Recent Advancements in MPNs

May 16th 2017

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Ongoing AML Trials of Novel Agents Could Shift Field

May 15th 2017

Aref Al-Kali, MD, discusses some of the recent advancements, exciting ongoing trials, and largest unanswered questions in AML.